Danaher Co. (NYSE:DHR) Shares Sold by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC lessened its holdings in Danaher Co. (NYSE:DHR) by 3.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,421 shares of the conglomerate’s stock after selling 538 shares during the period. Alpha Omega Wealth Management LLC’s holdings in Danaher were worth $4,009,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of DHR. Czech National Bank increased its position in shares of Danaher by 4.2% during the third quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock valued at $36,404,000 after acquiring an additional 5,320 shares during the last quarter. AMF Tjanstepension AB purchased a new position in shares of Danaher during the 3rd quarter worth approximately $5,923,000. Trust Co of the South acquired a new stake in Danaher in the 3rd quarter valued at approximately $372,000. Massmutual Trust Co. FSB ADV raised its position in Danaher by 2.4% in the third quarter. Massmutual Trust Co. FSB ADV now owns 101,103 shares of the conglomerate’s stock valued at $28,109,000 after purchasing an additional 2,344 shares during the period. Finally, Abacus Planning Group Inc. lifted its stake in Danaher by 9.2% during the third quarter. Abacus Planning Group Inc. now owns 5,937 shares of the conglomerate’s stock worth $1,650,000 after purchasing an additional 498 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Evercore ISI boosted their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Robert W. Baird upped their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Stephens initiated coverage on shares of Danaher in a research report on Tuesday. They issued an “overweight” rating and a $315.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Stock Performance

Shares of DHR opened at $270.68 on Friday. The company has a market capitalization of $200.49 billion, a price-to-earnings ratio of 45.88, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $271.15 and a 200 day moving average price of $258.43.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm posted $2.05 EPS. The company’s revenue was down 2.9% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.